Federal drug policy has a habit of mistaking harshness for seriousness. The Drug Enforcement Administration’s latest move against 7-hydroxymitragynine, better known as 7-OH, is a case in point.
On July 6, the DEA published a notice of intent to place products containing 7-OH above a prescribed threshold into Schedule I of the Controlled Substances Act, the same category of drugs like heroin and LSD. The order could take effect in early August and remain in force for two years, with a possible third. Once it does, unauthorized possession, manufacture, sale, importation, and even research would be subject to the controls and penalties applied to illicit drugs.
This rushed action is ignorant of the experience of millions of Americans who use the product as a safer alternative to opioids to manage chronic pain, mental health, and opioid withdrawals. A blanket ban will limit production of safe products and potentially push many consumers back toward the use of illicit opioids.
Rather than enacting a hasty ban, the DEA should move at a pace that allows the exploration of medical and safety questions to help determine the most appropriate regulation.
The powerful compound profile of 7-OH, a derivative of the kratom leaf, holds incredible potential. Every reasonable mind understands that this drug is meant only for adults and deserves scrutiny—its unregulated potency is the real problem. But the federal government’s own arguments on banning it show they are reaching for the wrong tool.
Schedule I is a declaration that a substance has no accepted use and cannot be studied freely or sold under any circumstance short of a criminal one. Logic necessitates that this extraordinary threshold must contain ample evidence to justify its use, but the DEA’s own published filing does not back up its condemnation of 7-OH.
Start with what the government itself admits it doesn’t know. Last year at a press conference where federal officials first previewed this effort to curtail the sale of 7-OH, a reporter asked a penetrating question to then-FDA Commissioner Dr. Marty Makary: how many deaths has 7-OH caused on its own?
The honest answer, then and now, is that regulators cannot cleanly point to one.
However, Makary didn’t dispute this so much as concede it. He sidestepped the question and complained that data on 7-OH remains thin and that the government is “just starting to understand” the compound.
That is a reasonable thing to say about a substance regulators plan to study further. But It is a troubling thing to say about a substance regulators are about to place in the same legal category as heroin.
Nearly a year later, the DEA’s own formal scheduling notice still reflects many of the same uncertainties.
Rather than building its case on controlled studies or a clear body of confirmed fatalities, the notice leans heavily on adverse-event reports that are self-selected and unverified. Remarkably the notice treats online “reddit mentions” of 7-OH problems akin to empirical evidence. Throughout the notice it also referrers to self-labeled “anecdotal information” as the basis for the government’s rational to enact the ban.
This is frankly embarrassing behavior from federal government regulators.
The problem is that the DEA ignores the logic jumps in their presentation. They move from evidence of risk to their predetermined solution of a Schedule I classification without demonstrating why narrower controls would be inadequate. That missing comparative analysis is the weakness at the center of the government’s case.
Further evidence of the federal government’s backward protocol behavior is their limited call for public comment. The U.S. Department of Health and Human Services is accepting public comments through July 31 on what concentration of 7-OH constitutes an imminent hazard. It is not asking whether temporary scheduling itself is justified.
That is a implicit admission of what regulators don’t know. Effectively, the government has announced its intention to impose Schedule I while still seeking evidence about where the danger threshold should be drawn. This shows federal regulators know the science is unsettled, but they still want to move forward on their preset conclusion of an out-right-ban.
An honest DEA would pause the order, answer the science question first, and build policy around the evidence rather than asking the evidence to catch up with a decision already made.
Smart regulation is the more appropriate solution, but it requires harder work. Federal standards could distinguish between pure 7-OH products and demonstratively dangerous knockoffs such as synthetically made products containing MGM-16. Furthermore, setting potency caps and purity standards, requiring lab testing and honest labeling, restricting sales to minors, and funding the research needed to actually answer the questions the DEA admits it can’t answer yet would all improve market safety for American consumers.
Congress and the FDA possess tools short of Schedule I to address concentrated, high-risk 7-OH products without burdening research or criminalizing responsible consumers. Several states have already built exactly this kind of statutory framework through kratom consumer-protection laws. The federal government could learn from them instead of leapfrogging past them into prohibition.
There is a real conversation to be had about how 7-OH products should be regulated, who should be able to sell them, and what warnings consumers deserve. The DEA’s notice shortcuts that conversation rather than resolving it. Prohibition is the easiest lever for an agency to pull, but easy isn’t the same as evidence based.
If the government is going to use its most powerful legal tool against a substance millions of Americans already use to manage pain, it owes the public more than a notice built on logic gaps it hasn’t filled in and reports it hasn’t verified. Right now, that’s what it’s offering